LICs frequency in CD34+ and CD34− cell fractions of NPM1-mutated AML
| Patient code . | Fraction (purity) . | Dose, ×106 . | LIC frequency (95% CI) . | LICs/106 MNCs . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2 . | 1 . | 0.5 . | 0.2 . | 0.1 . | 0.01 . | 0.001 . | ||||
| 17 | CD34+ | — | — | — | 3/4 | 4/4 | 3/4 | 0/2 | 1 in 50 400 | 5.4 |
| (98.3%) | (19 967–127 223) | |||||||||
| 17 | CD34− | — | — | — | 0/3 | 0/4 | 0/4 | — | — | — |
| (90%) | ||||||||||
| 22R | CD34+ | 3/3 | 2/2 | — | — | 4/4 | 0/4 | — | 1 in 41704 | 18 |
| (99.9%) | (13 820–125 855) | |||||||||
| 34 | CD34+ | — | 2/3 | 3/5 | 4/4 | 0/4 | — | — | 1 in 448 907 | 0.11 |
| (96.5%) | (214 463–939 640 | |||||||||
| 34 | CD34− | — | 0/4 | 0/4 | 0/4 | 0/4 | — | — | — | — |
| (96%) | ||||||||||
| Patient code . | Fraction (purity) . | Dose, ×106 . | LIC frequency (95% CI) . | LICs/106 MNCs . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2 . | 1 . | 0.5 . | 0.2 . | 0.1 . | 0.01 . | 0.001 . | ||||
| 17 | CD34+ | — | — | — | 3/4 | 4/4 | 3/4 | 0/2 | 1 in 50 400 | 5.4 |
| (98.3%) | (19 967–127 223) | |||||||||
| 17 | CD34− | — | — | — | 0/3 | 0/4 | 0/4 | — | — | — |
| (90%) | ||||||||||
| 22R | CD34+ | 3/3 | 2/2 | — | — | 4/4 | 0/4 | — | 1 in 41704 | 18 |
| (99.9%) | (13 820–125 855) | |||||||||
| 34 | CD34+ | — | 2/3 | 3/5 | 4/4 | 0/4 | — | — | 1 in 448 907 | 0.11 |
| (96.5%) | (214 463–939 640 | |||||||||
| 34 | CD34− | — | 0/4 | 0/4 | 0/4 | 0/4 | — | — | — | — |
| (96%) | ||||||||||
Mice used were NOD/SCID/IL2Rγnull. Values indicate no. of mice with AML/no. of mice evaluated. Details on immunophenotypic and immunohistochemical analysis of engrafted mice are shown in supplemental Table 4. Time of evaluation (weeks): +17 (patient 17); +10 (patient 22R); +4 (patient 34).
R indicates relapse; and —, not done.